Absorption of a mutagenic metabolite released from protein-bound residues of furazolidone

Environmental Toxicology and Pharmacology

Volumn 11, Issue 3-4, 2002, Pages 273-287

  Hoogenboom, Laurentius A P ^a   Van Bruchem, Gerard D ^a   Sonne, Kim ^b   Enninga, Ilona C ^c   Van Rhijn, Johannes A ^a   Heskamp, Henri ^a   Huveneers Oorsprong, Margot B M ^d   Van Der Hoeven, Jan C M ^c   Kuiper, Harry A ^a  

^a WAGENINGEN UNIVERSITY   (Netherlands)

^b DANISH MEAT RESEARCH INSTITUTE   (Denmark)

^c Notox BV   (Netherlands)

^d NONE

Author keywords

Bound residues; Furazolidone; MAO inhibition; Nitrofurans

Indexed keywords

3 AMINO 2 OXAZOLIDINONE; 4 CHLOROBENZENESULFONAMIDE; AMINE OXIDASE (FLAVIN CONTAINING); BENZENESULFONAMIDE DERIVATIVE; DIMETHYL SULFOXIDE; FURAZOLIDONE; OXAZOLIDINONE DERIVATIVE; UNCLASSIFIED DRUG;

AMES TEST; ANIMAL TISSUE; ARTICLE; BONE MARROW CELL; CHROMOSOME ABERRATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG ABSORPTION; DRUG BINDING; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG RELEASE; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN CELL; LIQUID CHROMATOGRAPHY; LIVER CELL; LIVER MICROSOME; LYMPHOCYTE; MALE; MASS SPECTROMETRY; MICRONUCLEUS TEST; NONHUMAN; PRIORITY JOURNAL; RAT; STOMACH PH; SWINE;

ANIMALIA; GYMNOMYZA SAMOENSIS; SALMONELLA; SUS SCROFA;

EID: 0036290175     PISSN: 13826689     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1382-6689(02)00013-3     Document Type: Article

References (35)

1. Inhibition of monoamine oxidase by furazolidone in the chicken and the influence of the alimentary flora thereon
2. Inhibition of monoamine oxidase in chickens and ducklings by a microbial metabolite of furazolidone
3. Cambendazole and nondrug molecules in tissue residues
4. Mutagenicity testing with the Salmonella/hepatocyte and the Salmonella/microsome assays
5. Bovine liver dihydropyrimidine amidohydrolase: Purification, properties, and characterization as a zinc metalloenzyme
6. Human peripheral blood lymphocytes for the analysis of chromosome abberrations in mutagen tests
7. Part V. New Animal Drugs. Furazolidone (NF-180)
8. 14C]furazolidone residues in swine tissues
9. The enzymatic hydrolysis-activation of the adriamycin cardioprotective agent (+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane
10. The bone marrow micronucleus test
11. The use of porcine hepatocytes for biotransformation studies of veterinary drugs
12. The use of pig hepatocytes to study the nature of protein-bound metabolites of furazolidone; A new analytical method for their detection
13. The use of pig hepatocytes to study the inhibition of monoamine oxidase by furazolidone
14. Depletion kinetics of protein-bound furazolidone metabolites containing an intact side-chain
15. Study on the role of glutathione in the biotransformation and toxicity of furazolidone using pig hepatocytes
16. Analysis of protein-bound metabolites of furazolidone and furaltadone in pig liver by high performance liquid chromatography and liquid chromatography-mass spectrometry
17. Bioassay of pesticides and industrial chemicals for tumoigenicity in mice: A preliminary note
18. 14C-furazolidone metabolites to the muscular and hepatic proteins of trout
19. Toxicological significance of covalently bound drug residues
20. Revised methods for the Salmonella mutagenicity test
21. Mutagenicity of nitrofuran derivatives: Review
22. The bioavailability of residues of the furazolidone metabolite 3-amino-2-oxazolidinone in porcine tissues and the effect of cooking upon residue concentrations
23. The prevalence and possible causes of bound and extractable residues of the furazolidone metabolite 3-amino-2-oxazolidinone in porcine tissues
24. Hemmung der mono-aminoxydase durch bakteriostatisch wirksame nitrofuranderivate
25. A simplification of the protein assay method of Lowry et al. which is more generally applicable
26. Inhibition of monoamine oxidase in man by furazolidone
27. Toxicological significance of covalently-bound residues
28. The micronucleus test
29. The anti-monoamine oxidase effects of furazolidone
30. 14C-furazolidone in piglets upon oral administration during 10 days and its interaction with tissue macro-molecules
31. Quantitative studies of the metabolism of furazolidone by rat liver microsomes
32. Identification of a reactive intermediate of furazolidone formed by swine liver microsomes
33. Reversible interaction of a reactive intermediate derived from furazolidone with glutathione and protein
34. In vivo and in vitro metabolic studies of furazolidone: A risk evaluation
35. Inhibition of monoamine oxidase by furazolidone in germ-free rats